Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, as of July 2, 2025, Pluvicto® (lutetium (177Lu) vipivotide tetraxetan injection) is publicly reimbursed in Quebec for ...

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a prescription drug that’s used to treat prostate cancer in certain situations. Pluvicto comes as a solution for injection or infusion.

Pluvicto (lutetium [177Lu] vipivotide tetraxetan), which won FDA approval in 2022, is fast becoming the dominant RLT for prostate cancer, according to GlobalData.

Pluvicto first got FDA approval on March 23, 2022, but this new expanded approval triples the number of patients eligible to receive the drug, according to a Novartis press release.

Pluvicto is designed to seek out and bind to cancer cells that express PSMA. Once attached, it delivers a small, targeted dose of radiation directly to the cancer cells — killing them while ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...

While PLUVICTO is not a cure for mCRPC, men who received PLUVICTO plus standard therapy lived longer and saw their tumors shrink or disappear at higher rates, compared to men who only received ...

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...

Pluvicto is marketed and sold by Novartis and generated sales of $1.39 billion in 2024. ATNM-400 is a highly innovative, first-in-class prostate cancer candidate in comparison to Pluvicto and the ...

Pluvicto pushes earlier in prostate cancer play. From my colleague Allison DeAngelis: Just a couple of months after getting a new approval for its blockbuster prostate cancer drug Pluvicto ...

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage for a ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...